HK1097263A1 - Fused ring nk1 antagonists - Google Patents
Fused ring nk1 antagonistsInfo
- Publication number
- HK1097263A1 HK1097263A1 HK07102344.2A HK07102344A HK1097263A1 HK 1097263 A1 HK1097263 A1 HK 1097263A1 HK 07102344 A HK07102344 A HK 07102344A HK 1097263 A1 HK1097263 A1 HK 1097263A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antagonists
- fused ring
- fused
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56034304P | 2004-04-07 | 2004-04-07 | |
PCT/US2005/011726 WO2005100358A1 (en) | 2004-04-07 | 2005-04-06 | Fused ring nk1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1097263A1 true HK1097263A1 (en) | 2007-06-22 |
Family
ID=34966309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07102344.2A HK1097263A1 (en) | 2004-04-07 | 2007-03-01 | Fused ring nk1 antagonists |
Country Status (12)
Country | Link |
---|---|
US (1) | US7498438B2 (de) |
EP (1) | EP1747221B1 (de) |
JP (1) | JP2007532561A (de) |
CN (1) | CN1964969A (de) |
AR (1) | AR048526A1 (de) |
AT (1) | ATE435226T1 (de) |
CA (1) | CA2562138A1 (de) |
DE (1) | DE602005015210D1 (de) |
ES (1) | ES2327654T3 (de) |
HK (1) | HK1097263A1 (de) |
TW (1) | TWI303246B (de) |
WO (1) | WO2005100358A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354922B2 (en) * | 2004-12-14 | 2008-04-08 | Schering Corporation | Bridged ring NK1 antagonists |
US20080234280A1 (en) * | 2005-08-01 | 2008-09-25 | Mcmurray Gordon | Use of Mc4 Receptor Agonist Compounds |
JP5352446B2 (ja) | 2006-04-05 | 2013-11-27 | オプコ ヘルス, インコーポレイテッド | 8−[{1−(3,5−ビス−(トリフルオロメチル)フェニル)−エトキシ}−メチル]−8−フェニル−1,7−ジアザ−スピロ[4.5]デカン−2−オンの塩酸塩およびその調製プロセス |
AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
EP2346823B1 (de) | 2008-09-05 | 2015-08-19 | OPKO Health, Inc. | Zwischenprodukte für die synthese von 8-[{1-(3,5-bis(trifluormethyl)phenyl)ethoxy}methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-onverbindungen" |
CN108148060B (zh) * | 2016-12-05 | 2020-06-19 | 四川科伦博泰生物医药股份有限公司 | 取代的杂环化合物及其衍生物,其药物组合物、制备方法及用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2654725B1 (fr) * | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent. |
DE69920516T2 (de) | 1998-12-23 | 2005-12-01 | Schering Corp. | Substituierte oxime und hydrazone als neurokinin antagonisten |
GB0017256D0 (en) * | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
-
2005
- 2005-04-06 DE DE602005015210T patent/DE602005015210D1/de active Active
- 2005-04-06 AT AT05737542T patent/ATE435226T1/de not_active IP Right Cessation
- 2005-04-06 CN CNA2005800182047A patent/CN1964969A/zh active Pending
- 2005-04-06 ES ES05737542T patent/ES2327654T3/es active Active
- 2005-04-06 TW TW094110933A patent/TWI303246B/zh not_active IP Right Cessation
- 2005-04-06 CA CA002562138A patent/CA2562138A1/en not_active Abandoned
- 2005-04-06 EP EP05737542A patent/EP1747221B1/de active Active
- 2005-04-06 WO PCT/US2005/011726 patent/WO2005100358A1/en active Application Filing
- 2005-04-06 AR ARP050101361A patent/AR048526A1/es not_active Application Discontinuation
- 2005-04-06 US US11/100,226 patent/US7498438B2/en not_active Expired - Fee Related
- 2005-04-06 JP JP2007507488A patent/JP2007532561A/ja not_active Withdrawn
-
2007
- 2007-03-01 HK HK07102344.2A patent/HK1097263A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AR048526A1 (es) | 2006-05-03 |
EP1747221B1 (de) | 2009-07-01 |
JP2007532561A (ja) | 2007-11-15 |
WO2005100358A1 (en) | 2005-10-27 |
US20060040975A1 (en) | 2006-02-23 |
DE602005015210D1 (de) | 2009-08-13 |
ES2327654T3 (es) | 2009-11-02 |
TWI303246B (en) | 2008-11-21 |
ATE435226T1 (de) | 2009-07-15 |
TW200538099A (en) | 2005-12-01 |
EP1747221A1 (de) | 2007-01-31 |
CN1964969A (zh) | 2007-05-16 |
CA2562138A1 (en) | 2005-10-27 |
US7498438B2 (en) | 2009-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI348467B (en) | Nk1 antagonists | |
TWI318206B (en) | Histamine-3 receptor antagonists | |
IL174538A0 (en) | Thrombin receptor antagonists | |
HK1090922A1 (en) | Cgrp receptor antagonists cgrp | |
EP1820515A4 (de) | Stickstoffhaltige kondensierte ringverbindung und ihre verwendung | |
GB0404124D0 (en) | Antagonists of GIP | |
IL175084A0 (en) | Antagonists of the bradykinin b1 receptor | |
ZA200702790B (en) | Thrombin receptor antagonists | |
HK1111340A1 (en) | Dual nk1/nk3 antagonists against schizophrenia | |
EP1737446A4 (de) | Kondensierte heterozyklische verbindungen | |
IL237513A0 (en) | Piperazindiones as oxytocin receptor antagonists | |
IL190686A0 (en) | Il-21 receptor antagonists | |
IL163939A0 (en) | Nk1 antagonists | |
HK1097263A1 (en) | Fused ring nk1 antagonists | |
PL378753A1 (pl) | Antagoniści receptora CCR-3 | |
GB0422231D0 (en) | Synthetic prosthesis | |
ZA200808701B (en) | Fused ring thrombin receptor antagonists | |
SG131946A1 (en) | Ccr3 receptor antagonists | |
GB0302094D0 (en) | EP4 receptor antagonists | |
GB0401152D0 (en) | Kalima ring | |
GB0408064D0 (en) | 5-HT2B receptor antagonists | |
GB0408063D0 (en) | 5-HT2B receptor antagonists | |
GB0408062D0 (en) | 5-HT2B receptor antagonists | |
GB0317346D0 (en) | 5-ht2b receptor antagonists | |
IL183335A0 (en) | Leptin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130406 |